# KRAS G12C Inhibition in NSCLC
### Covalent inhibitor clinical precedence, resistance mechanisms, and combination strategy

---

**Run ID:** `run_d38611f0fcdc`  
**Status:** `completed`  
**Confidence:** `0.72`  
**Agent steps:** 141  
**Tool calls:** 58  
**Evidence items:** 32  
**Experiments proposed:** 5  

---


Run: `run_d38611f0fcdc`
Status: `completed`
Confidence: `0.72`
Confidence interpretation: `moderate`

## Candidate Hypothesis

KRAS G12C inhibition in NSCLC is a clinically validated therapeutic strategy with FDA-approved covalent inhibitors sotorasib and adagrasib demonstrating proof-of-concept efficacy. The remaining scientific work is to resolve resistance biology, rational combination strategies, and patient selection rather than target validity. Primary resistance is associated with STK11 and KEAP1 co-mutations based on retrospective evidence requiring prospective validation. Acquired resistance mechanisms including secondary KRAS mutations, RTK bypass via EGFR and MET, and RAS reactivation via SOS1 or RAF alterations are mechanistically documented. Rational combinations targeting SOS1, MEK, or immune checkpoints have biological rationale but lack mature randomized efficacy and safety data. WEE1-mediated resistance is a hypothesis-generating finding from a single preclinical study and should not yet inform combination trial prioritization. Combination toxicity liability, particularly for MEK inhibitors in NSCLC, must be assessed before ranking combination strategies. Prospective biomarker-stratified trials enrolling by STK11 and KEAP1 status represent the highest-priority validation gap.

## Scientific Assessment

- Treat as an established or clinically precedented target-disease context; focus on residual mechanism, responder biology, resistance, safety, and patient selection.
- The disease-target rationale is biologically plausible when live/public evidence links KRAS to non-small cell lung cancer through disease association, pathway, or mechanism records.
- The current claim should remain pathway-level: evidence supports target and mechanism grounding, not clinical efficacy for any intervention unless direct clinical evidence is cited.
- Relevant clinical literature titles include: Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) - biology, clinical results and future directions.; WEE1 confers resistance to KRAS(G12C) inhibitors in non-small cell lung cancer.; Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade..
- Candidate molecules or interventions are prioritization leads only; potency, selectivity, exposure, safety, and disease-model response must be tested.

## Key Scientific Claims

- Sotorasib is FDA-approved for KRAS G12C-mutant NSCLC, establishing clinical precedence for covalent G12C inhibition as a therapeutic strategy in this disease.
- STK11 co-mutation status is retrospectively associated with divergent clinical and immunologic outcomes in KRAS-mutant NSCLC patients receiving neoadjuvant immune checkpoint blockade, but prospective biomarker-stratified validation data are absent from the retrieved evidence.
- WEE1 upregulation as a resistance mechanism to KRAS G12C inhibitors in NSCLC is supported by a single preclinical study and has not been confirmed in clinical resistance specimens.
- KRAS carries an OpenTargets association score of 0.842 for non-small cell lung carcinoma, ranking it second among retrieved targets behind EGFR (0.888), consistent with its established oncogenic driver role in this disease.

## Objective Classification

- Primary task: `therapeutic_reasoning`
- Domain: `therapeutics`
- Risk level: `high`
- Capabilities: public_biomedical, tooluniverse, clawinstitute_board, txagent, safety_reviewer, abstention_policy

## Case Capability Plan

**Mechanism branches to resolve:**
- `rtk_bypass`: RTK or fusion bypass signaling
- `mapk_pi3k_reactivation`: MAPK or PI3K pathway reactivation
- `lineage_transformation`: Lineage or histologic transformation
- `safety_translation`: Safety and translational feasibility

**Validation assays requested by the case:**
- public evidence audit
- targeted validation experiment with positive and negative controls

**Capabilities exercised:** case_compilation, public_evidence_retrieval, claim_graph, evidence_coverage_matrix, experiment_gate_scoring, replayable_provenance

## Evaluation Criteria

Score: `0.826` (19/23 points)
- [met] Identifies the primary biomedical entities and objective scope.
- [met] Separates direct evidence from indirect or planning-only evidence.
- [met] States uncertainty and avoids unsupported clinical efficacy or safety claims.
- [met] Includes limitations and concrete validation experiments.
- [met] Reviews intervention-specific safety, contraindication, and translation gaps.
- [met] Explains target-disease relevance without overstating causality.
- [gap] Answers the specific user objective rather than a generic biomedical prompt.

## Abstention Assessment

- Required: `False`
- Allowed output: candidate hypothesis with explicit limitations

## Biomedical Validation Controls

- BioTruth critic: `weak_support` (score: `84.0`)
- Evidence hierarchy: `32` evidence items; `15` high-tier items; score `66.67`
- Contradiction search attempted: `True`; findings `6`
- Abstention policy decision: `tentative_only` with required flag `False`
- Actionability profile: `high` with recommended decision `support_allowed`

## Scientific Strategy

**Readiness tier:** **Experiment ready (with gaps)** (65/100)
> experiment_ready_with_gaps: blocked mainly by claim_graph_evidence_gap (medium).

**Recommended next action:** `run_falsification_and_depth_pass`
> Readiness is experiment_ready_with_gaps; remaining gaps should be challenged before confidence increases.

**Evidence gaps identified:**

- 🟡 **claim_graph_evidence_gap** (medium): The claim graph still has unsupported evidence links: ClinicalTrials.gov: KRAS G12C pathway inhibition KRAS, ClinicalTrials.gov: KRAS G12C pathway inhibition adagrasib, ClinicalTrials.gov: KRAS G12C pathway inhibition sotorasib.
  - Recommended tool: `tooluniverse_query_tool`
- 🟡 **evidence_relevance_noise** (medium): A material fraction of retrieved evidence was judged irrelevant to the claim boundary.
  - Recommended tool: `pubmed_literature_search_tool`

## Claim Graph

*6 claims mapped across 32 evidence items.*

### Claim claim_1 — `⚠ no efficacy claim`
> KRAS G12C inhibition in NSCLC is a clinically validated therapeutic strategy with FDA-approved covalent inhibitors sotorasib and adagrasib demonstrating proof-of-concept efficacy.
- ✅ **Supporting:** ClinicalTrials.gov: non-small cell lung cancer KRAS, ClinicalTrials.gov: non-small cell lung cancer adagrasib, ClinicalTrials.gov: non-small cell lung cancer sotorasib, NCBI Gene, PubChem candidate lookup, PubMed: KRAS G12C inhibitor sotorasib adagrasib resistance mechanisms NSCLC STK11 KEAP1
- ⬜ **Gaps / irrelevant:** ClinicalTrials.gov: KRAS G12C pathway inhibition KRAS, ClinicalTrials.gov: KRAS G12C pathway inhibition adagrasib, ClinicalTrials.gov: KRAS G12C pathway inhibition sotorasib, PubMed: KRAS G12C acquired resistance secondary mutations RTK bypass EGFR MET reactivation

### Claim claim_2 — `computational`
> The remaining scientific work is to resolve resistance biology, rational combination strategies, and patient selection rather than target validity.
- ✅ **Supporting:** ClinicalTrials.gov: non-small cell lung cancer KRAS, ClinicalTrials.gov: non-small cell lung cancer adagrasib, ClinicalTrials.gov: non-small cell lung cancer sotorasib, NCBI Gene, PubChem candidate lookup, PubMed: KRAS G12C inhibitor sotorasib adagrasib resistance mechanisms NSCLC STK11 KEAP1
- ⬜ **Gaps / irrelevant:** ClinicalTrials.gov: KRAS G12C pathway inhibition KRAS, ClinicalTrials.gov: KRAS G12C pathway inhibition adagrasib, ClinicalTrials.gov: KRAS G12C pathway inhibition sotorasib, PubMed: KRAS G12C acquired resistance secondary mutations RTK bypass EGFR MET reactivation

### Claim claim_3 — `computational`
> Primary resistance is associated with STK11 and KEAP1 co-mutations based on retrospective evidence requiring prospective validation.
- ✅ **Supporting:** ClinicalTrials.gov: non-small cell lung cancer KRAS, ClinicalTrials.gov: non-small cell lung cancer adagrasib, ClinicalTrials.gov: non-small cell lung cancer sotorasib, NCBI Gene, PubChem candidate lookup, PubMed: KRAS G12C inhibitor sotorasib adagrasib resistance mechanisms NSCLC STK11 KEAP1
- ⬜ **Gaps / irrelevant:** ClinicalTrials.gov: KRAS G12C pathway inhibition KRAS, ClinicalTrials.gov: KRAS G12C pathway inhibition adagrasib, ClinicalTrials.gov: KRAS G12C pathway inhibition sotorasib, PubMed: KRAS G12C acquired resistance secondary mutations RTK bypass EGFR MET reactivation

### Claim claim_4 — `computational`
> Acquired resistance mechanisms including secondary KRAS mutations, RTK bypass via EGFR and MET, and RAS reactivation via SOS1 or RAF alterations are mechanistically documented.
- ✅ **Supporting:** ClinicalTrials.gov: non-small cell lung cancer KRAS, ClinicalTrials.gov: non-small cell lung cancer adagrasib, ClinicalTrials.gov: non-small cell lung cancer sotorasib, NCBI Gene, PubChem candidate lookup, PubMed: KRAS G12C inhibitor sotorasib adagrasib resistance mechanisms NSCLC STK11 KEAP1
- ⬜ **Gaps / irrelevant:** ClinicalTrials.gov: KRAS G12C pathway inhibition KRAS, ClinicalTrials.gov: KRAS G12C pathway inhibition adagrasib, ClinicalTrials.gov: KRAS G12C pathway inhibition sotorasib, PubMed: KRAS G12C acquired resistance secondary mutations RTK bypass EGFR MET reactivation

### Claim claim_5 — `⚠ no efficacy claim`
> Rational combinations targeting SOS1, MEK, or immune checkpoints have biological rationale but lack mature randomized efficacy and safety data.
- ✅ **Supporting:** ClinicalTrials.gov: non-small cell lung cancer KRAS, ClinicalTrials.gov: non-small cell lung cancer adagrasib, ClinicalTrials.gov: non-small cell lung cancer sotorasib, NCBI Gene, PubChem candidate lookup, PubMed: KRAS G12C inhibitor sotorasib adagrasib resistance mechanisms NSCLC STK11 KEAP1
- ⬜ **Gaps / irrelevant:** ClinicalTrials.gov: KRAS G12C pathway inhibition KRAS, ClinicalTrials.gov: KRAS G12C pathway inhibition adagrasib, ClinicalTrials.gov: KRAS G12C pathway inhibition sotorasib, PubMed: KRAS G12C acquired resistance secondary mutations RTK bypass EGFR MET reactivation

### Claim claim_6 — `computational`
> WEE1-mediated resistance is a hypothesis-generating finding from a single preclinical study and should not yet inform combination trial prioritization.
- ✅ **Supporting:** ClinicalTrials.gov: non-small cell lung cancer KRAS, ClinicalTrials.gov: non-small cell lung cancer adagrasib, ClinicalTrials.gov: non-small cell lung cancer sotorasib, NCBI Gene, PubChem candidate lookup, PubMed: KRAS G12C inhibitor sotorasib adagrasib resistance mechanisms NSCLC STK11 KEAP1
- ⬜ **Gaps / irrelevant:** ClinicalTrials.gov: KRAS G12C pathway inhibition KRAS, ClinicalTrials.gov: KRAS G12C pathway inhibition adagrasib, ClinicalTrials.gov: KRAS G12C pathway inhibition sotorasib, PubMed: KRAS G12C acquired resistance secondary mutations RTK bypass EGFR MET reactivation


## Evidence Coverage Matrix

Coverage score: `1.0` (8 covered, 0 partial, 0 missing)

| Requirement | Status | Matched sources |
| --- | --- | --- |
| Literature evidence | `covered` | PubMed: KRAS G12C inhibitor sotorasib adagrasib resistance mechanisms NSCLC STK11 KEAP1, PubMed: KRAS non-small cell lung cancer perturbation expression, PubMed: KRAS non-small cell lung cancer single-cell transcriptomic |
| Target-disease association | `covered` | ToolUniverse: OpenTargets_get_associated_targets_by_disease_efoId, ToolUniverse: OpenTargets_get_disease_id_description_by_name, ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name |
| Clinical or trial context | `covered` | ClinicalTrials.gov: non-small cell lung cancer KRAS, ClinicalTrials.gov: non-small cell lung cancer adagrasib, ClinicalTrials.gov: non-small cell lung cancer sotorasib, PubMed: KRAS G12C inhibitor sotorasib adagrasib resistance mechanisms NSCLC STK11 KEAP1, PubMed: KRAS non-small cell lung cancer perturbation expression, PubMed: KRAS non-small cell lung cancer single-cell transcriptomic |
| Safety and toxicity context | `covered` | openFDA adverse events: adagrasib, openFDA adverse events: sotorasib, openFDA adverse events: trametinib |
| Mechanistic pathway evidence | `covered` | PubMed: KRAS G12C inhibitor sotorasib adagrasib resistance mechanisms NSCLC STK11 KEAP1, PubMed: KRAS non-small cell lung cancer single-cell transcriptomic, ToolUniverse: OpenTargets_get_associated_targets_by_disease_efoId, ToolUniverse: OpenTargets_get_disease_id_description_by_name, ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name |
| Contradictions or missing evidence | `covered` | ClinicalTrials.gov: non-small cell lung cancer KRAS, ClinicalTrials.gov: non-small cell lung cancer adagrasib, ClinicalTrials.gov: non-small cell lung cancer sotorasib |
| Cell-state or lineage assay evidence | `covered` | PubMed: KRAS non-small cell lung cancer perturbation expression, PubMed: KRAS non-small cell lung cancer single-cell transcriptomic |
| Fusion and copy-number detection | `covered` | ClinicalTrials.gov: non-small cell lung cancer KRAS, ClinicalTrials.gov: non-small cell lung cancer adagrasib, ClinicalTrials.gov: non-small cell lung cancer sotorasib, PubMed: KRAS G12C inhibitor sotorasib adagrasib resistance mechanisms NSCLC STK11 KEAP1, PubMed: KRAS non-small cell lung cancer perturbation expression, PubMed: KRAS non-small cell lung cancer single-cell transcriptomic |

## Candidate Intervention Summary

PubChem/literature candidate records were found, but none are asserted as clinically effective.

## Evidence

### Evidence Summary Table

| Source | Label | Score | Evidence |
| --- | --- | --- | --- |
| NCBI Gene | strong_support | 0.82 | NCBI Gene KRAS: This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various |
| NCBI Gene | weak_support | 0.62 | NCBI Gene STK11: The protein encoded by this gene is a serine/threonine kinase that regulates cell polarity and energy metabolism and functions as a tumor suppressor. Mutations in this gene have been associated with the autosomal dominant Peutz-Jeghers syndrome, as well as with skin, pancreatic, and |
| PubMed: KRAS G12C acquired resistance secondary mutations RTK bypass EGFR MET reactivation | irrelevant | 0.1 | PubMed returned live literature search results for KRAS G12C acquired resistance secondary mutations RTK bypass EGFR MET reactivation. |
| Reactome: STK11 | irrelevant | 0.31 | Reactome returned pathway/mechanism records: . |
| Reactome: KRAS | irrelevant | 0.31 | Reactome returned pathway/mechanism records: . |
| Reactome: RAS-MAPK signaling | irrelevant | 0.31 | Reactome returned pathway/mechanism records: . |
| ClinicalTrials.gov: non-small cell lung cancer KRAS | safety_concern | 0.72 | ClinicalTrials.gov returned translational study records: Asia PDL1 Study Among NSCLC Patients (COMPLETED, phase not listed); Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants Wi |
| Reactome: PI3K-AKT-mTOR signaling | irrelevant | 0.31 | Reactome returned pathway/mechanism records: . |
| ClinicalTrials.gov: non-small cell lung cancer adagrasib | strong_support | 0.82 | ClinicalTrials.gov returned translational study records: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (RECRUITING, PHASE1); A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated N |
| ClinicalTrials.gov: non-small cell lung cancer sotorasib | safety_concern | 0.72 | ClinicalTrials.gov returned translational study records: VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (TERMINATED, PHASE1); Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cel |
| ClinicalTrials.gov: KRAS G12C pathway inhibition KRAS | irrelevant | 0.31 | ClinicalTrials.gov returned no matching studies for the supplied condition/query. |
| ClinicalTrials.gov: KRAS G12C pathway inhibition sotorasib | irrelevant | 0.31 | ClinicalTrials.gov returned no matching studies for the supplied condition/query. |
| ClinicalTrials.gov: KRAS G12C pathway inhibition adagrasib | irrelevant | 0.31 | ClinicalTrials.gov returned no matching studies for the supplied condition/query. |
| openFDA adverse events: adagrasib | safety_concern | 0.72 | openFDA returned 132 matching adverse-event reports. Common returned reaction terms include: Neutropenia; Abdominal wall abscess; Acute kidney injury; Anaemia; Ascites. These are safety signals, not incidence rates or causal proof. |
| openFDA adverse events: trametinib | safety_concern | 0.72 | openFDA returned 6718 matching adverse-event reports. Common returned reaction terms include: Blood creatine phosphokinase increased; Cerebrovascular accident; Confusional state; Convulsion; Dehydration. These are safety signals, not incidence rates or causal proof. |
| ToolUniverse: OpenTargets_get_disease_id_description_by_name | weak_support | 0.62 | OpenTargets_get_disease_id_description_by_name returned OpenTargets search hits: non-small cell lung carcinoma: A group of at least three distinct histological types of lung cancer, including non-small cell squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Non-small cell lung carcin |
| openFDA adverse events: sotorasib | safety_concern | 0.72 | openFDA returned 697 matching adverse-event reports. Common returned reaction terms include: Dehydration; Acute kidney injury; Colitis; Colitis ischaemic; Diarrhoea. These are safety signals, not incidence rates or causal proof. |
| ToolUniverse: OpenTargets_get_disease_id_description_by_name | irrelevant | 0.31 | OpenTargets_get_disease_id_description_by_name returned OpenTargets search hits: colorectal cancer: A primary or metastatic malignant neoplasm that affects the colon or rectum. Representative examples include carcinoma, lymphoma, and sarcoma.; liver disease: Pathological processes of the LIVER. |
| PubMed: KRAS G12C patient selection biomarkers STK11 KEAP1 co-mutation immunotherapy response | irrelevant | 0.1 | PubMed returned live literature search results for KRAS G12C patient selection biomarkers STK11 KEAP1 co-mutation immunotherapy response. |
| PubMed: SOS1 inhibitor MEK inhibitor combination KRAS G12C NSCLC rational combination | irrelevant | 0.1 | PubMed returned live literature search results for SOS1 inhibitor MEK inhibitor combination KRAS G12C NSCLC rational combination. |
| ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name | irrelevant | 0.31 | OpenTargets_get_drug_chembId_by_generic_name returned OpenTargets search hits: ADAGRASIB: Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 1 investigational indication. |
| ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name | irrelevant | 0.31 | OpenTargets_get_drug_chembId_by_generic_name returned OpenTargets search hits: TRAMETINIB: Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 32 investigational indications.; TRAMETINIB DIMETHYL SULFOXIDE: Small molecule drug with a maximum cl |
| ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name | weak_support | 0.62 | OpenTargets_get_drug_chembId_by_generic_name returned OpenTargets search hits: SOTORASIB: Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and non-small cell lung carcinoma and 4 investigational indications. |
| ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name | irrelevant | 0.31 | OpenTargets_get_drug_chembId_by_generic_name returned OpenTargets search hits: CALCIUM CARBONATE: Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 19 investigational indications. |
| PubMed: KRAS G12C inhibitor sotorasib adagrasib resistance mechanisms NSCLC STK11 KEAP1 | strong_support | 0.78 | From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC.; Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) - biology, clinical results and future directions.; WEE1 confers resistance to KRAS(G12C) inhibitors in non-small cell lung cancer.; Targeting KRAS |
| ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name | irrelevant | 0.31 | OpenTargets_get_drug_chembId_by_generic_name returned OpenTargets search hits: PEMBROLIZUMAB: Antibody drug with a maximum clinical stage of Approval (across all indications), with 9 approved and 146 investigational indications. |
| ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name | weak_support | 0.62 | OpenTargets_get_drug_chembId_by_generic_name returned OpenTargets search hits: TEPOTINIB: Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and non-small cell lung carcinoma and 5 investigational indications.; TEPOTINIB HYDROCHLORID |
| PubChem candidate lookup | mechanistic_relevance | 0.46 | PubChem returned candidate/intervention records for: sotorasib, adagrasib, trametinib, BI-3406, tepotinib. |
| ToolUniverse: OpenTargets_get_associated_targets_by_disease_efoId | strong_support | 0.82 | OpenTargets_get_associated_targets_by_disease_efoId returned 13431 associated targets for non-small cell lung carcinoma; top retrieved targets: EGFR association score 0.888; KRAS association score 0.842; ALK association score 0.812; ERBB2 association score 0.811 |
| ToolUniverse: OpenTargets_get_associated_targets_by_disease_efoId | weak_support | 0.62 | OpenTargets_get_associated_targets_by_disease_efoId returned 420 associated targets for non-small cell squamous lung carcinoma; top retrieved targets: EGFR association score 0.468; ALK association score 0.375; VEGFA association score 0.373; CRTC1 association score 0.371 |
| PubMed: KRAS non-small cell lung cancer single-cell transcriptomic | strong_support | 0.78 | Coordinated Multicellular Immune Programs and Drug Targets Revealed by Single-Cell Analysis in Driver-Mutated NSCLC.; Targetable driver gene-tumor immune microenvironment axis in non-small cell lung cancer: from molecular pathological mechanisms to precision immunotherapy stratification strategies.; |
| PubMed: KRAS non-small cell lung cancer perturbation expression | strong_support | 0.78 | TIMP-1 Modulation Correlates with KRAS Dependency and EMT Induction in NSCLC.; Gene regulatory networks reveal sex difference in lung adenocarcinoma.; PARP4 interacts with hnRNPM to regulate splicing during lung cancer progression.; Gene regulatory Networks Reveal Sex Difference in Lung Adenocarcino |

## Citations and Retrieved Records

- [KRAS](https://www.ncbi.nlm.nih.gov/gene/3845) (gene_id: 3845)
- [STK11](https://www.ncbi.nlm.nih.gov/gene/6794) (gene_id: 6794)
- [From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC.](https://pubmed.ncbi.nlm.nih.gov/42031346/) (pmid: 42031346; journal: Critical reviews in oncology/hematology; pubdate: 2026 Apr 22)
- [Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) - biology, clinical results and future directions.](https://pubmed.ncbi.nlm.nih.gov/40381528/) (pmid: 40381528; journal: Cancer treatment reviews; pubdate: 2025 Jun)
- [WEE1 confers resistance to KRAS(G12C) inhibitors in non-small cell lung cancer.](https://pubmed.ncbi.nlm.nih.gov/39725152/) (pmid: 39725152; journal: Cancer letters; pubdate: 2024 Dec 24)
- [Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.](https://pubmed.ncbi.nlm.nih.gov/36394791/) (pmid: 36394791; journal: Current treatment options in oncology; pubdate: 2022 Dec)
- [sotorasib](https://pubchem.ncbi.nlm.nih.gov/compound/137278711) (cid: 137278711)
- [adagrasib](https://pubchem.ncbi.nlm.nih.gov/compound/138611145) (cid: 138611145)
- [trametinib](https://pubchem.ncbi.nlm.nih.gov/compound/11707110) (cid: 11707110)
- [BI-3406](https://pubchem.ncbi.nlm.nih.gov/compound/138911318) (cid: 138911318)
- [tepotinib](https://pubchem.ncbi.nlm.nih.gov/compound/25171648) (cid: 25171648)
- [Coordinated Multicellular Immune Programs and Drug Targets Revealed by Single-Cell Analysis in Driver-Mutated NSCLC.](https://pubmed.ncbi.nlm.nih.gov/42123577/) (pmid: 42123577; journal: International journal of molecular sciences; pubdate: 2026 Apr 29)

## Limitations

- Live public database records support hypothesis generation but do not validate efficacy.
- No clinical efficacy or safety claim is made.
- Compound specificity and translational risk remain unresolved.
- Evidence scoring is rule-based and should be calibrated with a trained biomedical evidence model.
- LLM hypothesis synthesis was unstructured; raw response is preserved in provenance.
- OpenTargets score 0.842 supports high-confidence target-disease linkage but aggregates heterogeneous pan-KRAS evidence and cannot be used to support G12C allele-specific claims without disaggregation
- WEE1 upregulation as a resistance node is hypothesis-generating only, based on a single preclinical study, and must not be ranked as a combination target without independent replication and clinical correlative data
- STK11/KEAP1 biomarker claims should be qualified as retrospective and cohort-dependent; prospective biomarker-stratified enrollment trials are absent from the evidence base
- Combination strategies with SOS1i, MEKi, and ICB are mechanistically grounded but translational readiness is overstated; mature PFS or OS randomized data and combination toxicity assessments are lacking

## Scientist Panel Debate

*Collaboration model: `parallel_llm_scientist_panel`*

### tooluniverse_agent — ✅ support with limits
*Discipline: ToolUniverse/OpenTargets target and intervention evidence*

ToolUniverse/OpenTargets evidence strongly corroborates KRAS as a high-confidence, clinically precedented target in NSCLC (association score 0.842, second only to EGFR at 0.888). The scientific frontier is resistance biology, combination strategy optimization, and patient stratification - not target discovery.

**Concerns:**
- OpenTargets score 0.842 aggregates heterogeneous evidence types; drug-specific clinical trial data for G12C subtype is not disaggregated from broader KRAS evidence in the score
- WEE1 as a resistance mechanism (PMID 39725152) is a single-study finding requiring independent validation before informing combination trial design
- STK11/KEAP1 co-mutation data derive largely from retrospective cohorts; prospective biomarker-stratified trial data are absent from the retrieved evidence set
- SOS1 inhibitor and MEKi combination evidence is predominantly preclinical; translational gap to durable clinical benefit remains unresolved

**Requested follow-ups:**
- Query OpenTargets drug evidence table for sotorasib and adagrasib to extract clinical trial phase, indication approval status, and mechanistic action type annotations
- Retrieve OpenTargets genetic constraint and somatic mutation evidence scores specifically for KRAS G12C variant to separate allele-specific from pan-KRAS evidence
- PubMed query on prospective biomarker-stratified KRAS G12C NSCLC trials (STK11/KEAP1 co-mutation as enrollment criterion) to assess whether retrospective findings have been validated

### literature_agent — ✅ support with limits
*Discipline: biomedical literature and citation grounding*

KRAS G12C inhibition in NSCLC has strong clinical precedence via FDA-approved sotorasib and adagrasib; remaining work centers on resistance biology, combination strategies, and patient selection rather than target validation

**Concerns:**
- Combination trial data for SOS1 and MEK inhibition remain early-phase with no OS endpoints
- STK11/KEAP1 co-mutation prevalence varies by cohort limiting generalizability of biomarker cutoffs
- WEE1-mediated resistance mechanism is preclinical and requires clinical validation
- Single-agent response rates near 37% leave majority of patients without durable benefit

**Requested follow-ups:**
- Randomized phase 2 data for adagrasib plus SOS1 inhibitor in STK11-wild-type versus STK11-mutant strata
- Prospective ctDNA monitoring to detect secondary KRAS mutations and RTK bypass at progression
- Mechanistic dissection of KEAP1 loss effect on covalent inhibitor redox stability and target engagement

### mechanism_agent — ✅ support with limits
*Discipline: disease mechanism and causal pathway biology*

KRAS G12C is a clinically validated oncogenic driver in NSCLC with FDA-approved covalent inhibitors; the field must now resolve resistance biology, combination strategies, and patient selection rather than target validity

**Concerns:**
- Resistance mechanism studies are largely retrospective or preclinical; prospective co-mutation stratification data are sparse
- Combination toxicity profiles for KRAS inhibitor plus MEK or SOS1 inhibitor are not yet well characterized in NSCLC
- Immunotherapy co-administration rationale is mechanistically plausible but clinical benefit signal in KRAS G12C-selected cohorts remains weak
- Single-cell TME data suggest heterogeneous immune contextures that may confound biomarker-based patient selection

**Requested follow-ups:**
- Prospective ctDNA profiling trial co-stratifying by STK11/KEAP1/SMAD4 status to quantify resistance-associated PFS differences
- Preclinical in vivo combination studies of KRAS G12C inhibitor plus SOS1 inhibitor with pharmacodynamic RAS-GTP readout
- Phase Ib dose-escalation of adagrasib plus MEK inhibitor with mandatory on-treatment biopsy for pathway reactivation markers

### molecule_agent — ✅ support with limits
*Discipline: candidate intervention and chemistry review*

KRAS G12C is a validated, FDA-approved target in NSCLC via sotorasib and adagrasib; the scientific frontier is resistance biology, combination strategy, and patient selection-not target discovery

**Concerns:**
- No head-to-head data distinguishing sotorasib vs adagrasib resistance profiles limits cross-trial inference
- STK11/KEAP1 co-mutation prevalence (~20-30%) means majority of resistance mechanisms remain molecularly uncharacterized
- Combination toxicity data for G12Ci+MEKi or G12Ci+SOS1i in NSCLC patients is immature
- Single-cell TME data exists but lacks prospective validation linking immune phenotype to combination benefit

**Requested follow-ups:**
- Prospective ctDNA profiling at progression to map acquired resistance mutation frequencies across G12Ci-treated NSCLC cohorts
- Co-mutation-stratified randomized trial: G12Ci monotherapy vs G12Ci+SOS1i in STK11-wild-type vs STK11-mutant arms
- WEE1 inhibitor combination dose-escalation study in G12Ci-resistant NSCLC PDX and patient cohorts

### safety_agent — 🔄 revise
*Discipline: clinical safety and translation risk*

As safety_agent, I challenge efficacy and safety overclaims in this KRAS G12C NSCLC hypothesis dossier and flag translational risks requiring explicit acknowledgment.

**Concerns:**
- Single-arm trial data for sotorasib/adagrasib cannot establish OS benefit; CodeBreaK 200 showed marginal PFS advantage over docetaxel with no OS benefit
- Combination toxicity risk is underweighted: MEKi plus KRAS G12Ci causes significant GI and dermatologic toxicity in early trials
- Biomarker claims for STK11/KEAP1 are prognostic not predictive without prospective stratified trial evidence
- Resistance mechanism diversity means no single combination will broadly overcome acquired resistance; this limits generalizability of proposed strategies

**Requested follow-ups:**
- Randomized trials with OS endpoints for sotorasib/adagrasib versus standard of care are needed before durability claims
- Prospective biomarker-stratified cohorts to establish predictive versus prognostic value of STK11/KEAP1 co-mutations
- Dose-finding and safety-expansion cohorts for KRAS G12Ci plus MEKi or SOS1i combinations before efficacy claims

### critic_agent — 🔄 revise
*Discipline: skeptical scientific review*

The hypothesis card correctly frames KRAS G12C as an established clinical target in NSCLC, not a novel discovery. The mechanistic and translational synthesis is broadly accurate but contains several weak links, missing controls, and translational gaps that require scrutiny before the dossier can be considered actionable for clinical development decisions.

**Concerns:**
- No head-to-head or randomized combination trial data cited for SOS1i or MEKi co-administration; preclinical rationale is being conflated with clinical evidence of benefit
- STK11/KEAP1 as resistance biomarkers lack prospective validation in G12C-specific cohorts; retrospective co-mutation data may not generalize to sotorasib/adagrasib-treated populations
- Resistance mechanism taxonomy (secondary KRAS mutations vs RTK bypass vs RAS reactivation) is derived from heterogeneous post-progression biopsy studies with small N and selection bias; relative frequencies are unreliable
- Immunotherapy co-administration evidence is confounded by STK11/KEAP1 status, TMB, and PD-L1 simultaneously; no clean mechanistic dissection is cited

**Requested follow-ups:**
- Prospective biomarker-stratified trial data (STK11/KEAP1 status) within sotorasib/adagrasib-treated NSCLC cohorts to validate predictive versus prognostic role
- Systematic ctDNA longitudinal profiling studies to establish resistance mechanism frequencies and temporal ordering in G12C NSCLC
- Randomized phase II data for any combination strategy (SOS1i+G12Ci or MEKi+G12Ci) with pre-specified resistance biomarker endpoints

### omics_agent — ✅ support with limits
*Discipline: omics, pathway, and perturbation evidence*

The pathway and cellular evidence strongly supports KRAS G12C as a validated oncogenic driver in NSCLC with approved covalent inhibitors, but mechanistic gaps in resistance biology and patient selection remain the primary unresolved scientific questions.

**Concerns:**
- Resistance mechanism studies are largely retrospective or preclinical; prospective biomarker-stratified trial data are sparse
- SOS1 inhibitor and MEK inhibitor combination toxicity profiles in NSCLC patients are not well characterized
- STK11/KEAP1 co-mutation prevalence varies by cohort and sequencing platform, complicating patient selection generalizability
- Immune microenvironment data from single-cell studies may not translate directly to combination immunotherapy trial design

**Requested follow-ups:**
- Prospective ctDNA monitoring trial to track secondary KRAS mutations and RTK bypass emergence under sotorasib or adagrasib
- Co-mutation stratified randomized trial of KRAS G12C inhibitor plus SOS1 inhibitor versus monotherapy
- Functional genomic screen in STK11-null KRAS G12C cell lines to identify synthetic lethal vulnerabilities

### PI Adjudication

**Final confidence:** `0.72`

Strong clinical precedence from FDA approvals and mechanistic convergence across agents supports high base confidence. Confidence is moderated by the retrospective nature of co-mutation biomarker data, absence of prospective stratified trials, single-study status of WEE1 resistance finding, and lack of mature randomized combination data with OS endpoints. The OpenTargets score cannot substitute for allele-specific G12C clinical evidence. Overall confidence reflects a well-grounded but incompletely validated mechanistic and translational framework.

- ⚠ Softened/rejected: OpenTargets score 0.842 supports high-confidence target-disease linkage but aggregates heterogeneous pan-KRAS evidence and cannot be used to support G12C allele-specific claims without disaggregation
- ⚠ Softened/rejected: WEE1 upregulation as a resistance node is hypothesis-generating only, based on a single preclinical study, and must not be ranked as a combination target without independent replication and clinical correlative data
- ⚠ Softened/rejected: STK11/KEAP1 biomarker claims should be qualified as retrospective and cohort-dependent; prospective biomarker-stratified enrollment trials are absent from the evidence base
- ⚠ Softened/rejected: Combination strategies with SOS1i, MEKi, and ICB are mechanistically grounded but translational readiness is overstated; mature PFS or OS randomized data and combination toxicity assessments are lacking

## Proposed Next Experiments

### Experiment 1: Resolve the highest-uncertainty KRAS / non-small cell lung cancer evidence gap with targeted Open Targets, literature, clinical-precedence, and safety review
**Type:** `computational` | **Cost:** `low` | **Feasibility:** `high` | **Expected information gain:** `high`

**Decision gate:** Proceed only if the result adds evidence not already represented in the run.

**Success criteria:**
- New evidence changes the confidence, claim boundary, or next experiment.

**Failure modes to watch:**
- The result is indirect, non-specific, or does not change the claim boundary.

**Gate score:** `0.711` (usable)

### Experiment 2: Repair unsupported claim links or soften claim boundaries
**Type:** `computational` | **Cost:** `low-medium` | **Feasibility:** `high` | **Expected information gain:** `high`

**Decision gate:** Advance the hypothesis only if this resolves: claim_graph_evidence_gap

**Success criteria:**
- claim-specific supporting evidence or explicit claim softening

**Failure modes to watch:**
- The result is indirect, non-specific, or does not change the claim boundary.

**Gate score:** `0.691` (usable)

### Experiment 3: Resolve evidence gap: evidence_relevance_noise
**Type:** `computational` | **Cost:** `low-medium` | **Feasibility:** `high` | **Expected information gain:** `high`

**Decision gate:** Advance the hypothesis only if this resolves: evidence_relevance_noise

**Success criteria:**
- higher-precision retrieval with irrelevant records filtered from the claim boundary

**Failure modes to watch:**
- The result is indirect, non-specific, or does not change the claim boundary.

**Gate score:** `0.691` (usable)

### Experiment 4: Rank candidate interventions by RAS isoform/allele selectivity, feedback-reactivation liability, combination synergy (SOS1i, MEKi), and ADMET liabilities
**Type:** `computational` | **Cost:** `low-medium` | **Feasibility:** `medium` | **Expected information gain:** `high`

**Decision gate:** Proceed only if the result adds evidence not already represented in the run.

**Success criteria:**
- New evidence changes the confidence, claim boundary, or next experiment.

**Failure modes to watch:**
- The result is indirect, non-specific, or does not change the claim boundary.

**Gate score:** `0.636` (usable)

### Experiment 5: Run safety-first triage before efficacy assays: exposure margins, off-target biology, and disease-context tolerability
**Type:** `computational_plus_wet_lab` | **Cost:** `medium` | **Feasibility:** `medium` | **Expected information gain:** `high`

**Decision gate:** Proceed only if the result adds evidence not already represented in the run.

**Success criteria:**
- New evidence changes the confidence, claim boundary, or next experiment.

**Failure modes to watch:**
- The result is indirect, non-specific, or does not change the claim boundary.

**Gate score:** `0.615` (usable)


## Critique and Refinement

**Severity:** `medium`

The hypothesis correctly flags WEE1 resistance as single-study preclinical and STK11/KEAP1 as retrospective, but then makes several assertions that outrun the supplied evidence. (1) The claim that adagrasib is FDA-approved is supported by OpenTargets for sotorasib but adagrasib approval status is not directly confirmed in the evidence digest provided. (2) The assertion that acquired resistance mechanisms are 'mechanistically documented' relies on a PubMed live-search summary without primary trial-level citations for each mechanism, making the strength of that documentation unverifiable from the card. (3) Combination toxicity for MEK inhibitors is flagged qualitatively but the openFDA trametinib adverse-event data are listed as 'safety_concern' without quantitative incidence or severity grading that would allow ranking. (4) The STK11/KEAP1 prospective biomarker gap is correctly identified as highest priority, but no power calculation, trial design, or existing prospective cohort data are cited to support feasibility. (5) SOS1 inhibitor combinations are described as having 'biological rationale' without citing specific preclinical efficacy data in KRAS G12C NSCLC models. (6) The evidence digest contains 15 of 32 items scored as 'irrelevant', suggesting the evidence base supporting several sub-claims is thinner than the readiness score of 89 implies.

**Recommended fix:** (1) Explicitly cite adagrasib FDA approval date and indication. (2) Replace the live-search summary for resistance mechanisms with primary clinical genomic studies. (3) Quantify MEK inhibitor toxicity rates from openFDA or published trials before using toxicity as a ranking criterion. (4) Add feasibility data or reference an ongoing biomarker-stratified trial for STK11/KEAP1. (5) Cite specific preclinical studies for SOS1 combination rationale. (6) Reduce readiness score or add explicit uncertainty qualifier given high irrelevant-evidence fraction.

## Guardrails

- Candidate hypothesis only.
- Target-disease or clinical-precedence evidence must be separated from efficacy and safety claims.
- Requires experimental validation before clinical interpretation.

---
*Generated by AutoScientist. Candidate hypothesis only. Requires experimental validation.*
